Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 9/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954003 | 0.87 | L3MBTL1 (0.49) | HRH3NOD2NOD1MEN1KMT2A | |
| SCHEMBL5621855 | 0.84 | NOD2 (0.46) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL2398795 | 0.81 | NOD2 (0.48) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL3091481 | 0.81 | NOD2 (0.46) | ELANENOD2NOD1MEN1KMT2A | |
| SCHEMBL38652509 | 0.81 | NOD2 (0.46) | ELANENOD2NOD1MEN1KMT2A | |
| SCHEMBL15670291 | 0.81 | L3MBTL1 (0.56) | NTRK1ELANEMEN1KMT2AKDM4E | |
| SCHEMBL30585515 | 0.80 | NOD2 (0.64) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL1392918 | 0.80 | NOD2 (0.64) | NOD2NOD1MEN1KMT2AKDM4E | |
| SCHEMBL31424255 | 0.80 | MEN1 (0.44) | HRH3NOD2NOD1MEN1KMT2A | |
| SCHEMBL14605045 | 0.79 | NTRK1 (0.79) | NTRK1CNR1KDM4ECRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828200-B1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | HOFFMANN LA ROCHE (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7375226-B2 | Bi- and tricyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1828200-A1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063709-A1 | BI- AND TRICYCLIC SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER I (GLYT-1) INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128713-A1 | (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128713-A1 | (6-Chloro-3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridin-2-yl)-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone; glyicne transporter 1 (GlyT-1) and N-methyl-D-aspartate (NMDA) receptors inhibitor; psychoses, schizophrenia, attention deficit disorders, Alzheimer's disease; cognition activator | GRIN1, GRIA1, GRM1 | NTRK1 718/4885CNR1 157/4885ELANE 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.